Noxafil: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 23: Line 23:
Noxafil is available in several forms, such as an oral suspension, gastro resistant tablets, and a concentrate (EMA). The pharmacokinetics and pharmacodynamics of Noxafil, specifically posaconazole, have been studied extensively and continue to be studied today to further improve the overall effectivenes of the drug <ref name="dekkers"/>.  
Noxafil is available in several forms, such as an oral suspension, gastro resistant tablets, and a concentrate (EMA). The pharmacokinetics and pharmacodynamics of Noxafil, specifically posaconazole, have been studied extensively and continue to be studied today to further improve the overall effectivenes of the drug <ref name="dekkers"/>.  
Some of the most commonly reported side effects include nausea, diarrhea, headaches, fever, vomiting, tiredness, and dizziness.  
Some of the most commonly reported side effects include nausea, diarrhea, headaches, fever, vomiting, tiredness, and dizziness.  
Posaconazole has not been found to be have significant dose-limiting toxicity and has more reduced drug-drug interactions than many other antifungals (formularyjournal)  
Posaconazole has not been found to be have significant dose-limiting toxicity and has more reduced drug-drug interactions than many other antifungals (formularyjournal).
It should be taken with food to help absorption and is generally taken 3 times a day in 200 mg doses.  For fungi that have been unmanageable through other treatments, 800 mg are given daily 2 or 4 times a day to treat infection <ref name="greer"> Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proceedings (Baylor University Medical Center). 2007;20(2):188-196. PMID: PMC1849883 </ref>
It should be taken with food to help absorption and is generally taken 3 times a day in 200 mg doses.  For fungi that have been unmanageable through other treatments, 800 mg are given daily 2 or 4 times a day to treat infection <ref name="greer"> Greer ND. Posaconazole (Noxafil): a new triazole antifungal agent. Proceedings (Baylor University Medical Center). 2007;20(2):188-196. PMID: PMC1849883 </ref>